Introduction
============

Given that they function as gene switches, signaling by nuclear receptors is ideally suited to analyses using genomics approaches. The last few years have seen the development of a number of techniques for analysis of gene expression and regulation on chromosome-wide or genome-wide scales. We will assess below the strengths and limitations and the complementarity of three general approaches for genome-wide identification of nuclear receptor target genes; expression profiling, ChIP-on-chip experiments, and *in silico* identification and mapping of hormone response elements, and discuss how these techniques have dramatically enhanced our understanding of the mechanisms and physiological consequences of nuclear receptor signaling.

Genome-wide expression profiling of nuclear receptor-regulated gene expression
==============================================================================

Microarray analysis
-------------------

Microarray technology was developed in the early 1990s to monitor the expression of many genes simultaneously \[[@r62]\]. Since then, the use of microarrays has become a powerful tool and a standard technique for analyzing the expression and regulation of thousands of genes in parallel. A DNA microarray consists of a glass slide containing thousands of DNA sequences fixed to the slide in a grid, each of which represents a portion of a gene. RNA samples under analysis are converted to cDNAs, labeled with fluorescent dyes, and hybridized to the array. Since the location and the sequence of the probe fixed in the array is known, the identity and relative abundance of sequences hybridized to the array can be determined \[[@r63]\]. There are two different types of DNA microarrays based on the types of probes used: cDNA microarrays and oligonucleotide microarrays. cDNA microarrays use probes generated by amplified cDNA (either from plasmids or amplified by RT-PCR). These probes are fixed on silane slides by covalently UV cross-linking the thymidine residues of the cDNA with the amine groups in the silane slide \[[@r73]\]. Oligonucleotide microarrays use \~25mer oligonucleotides complementary to a selected gene or EST sequence \[[@r57]\]. The arrays are designed *in silico* and placed in the slide. Array densities have increased rapid over the last few years, driven in part by rapid increases in genomic sequence and EST databases. The most recent human and mouse Affymetrix oligonucleotide arrays contain 47,000 and 37,000 gene sequences, respectively.

Applications of microarrays to analysis of nuclear receptor signaling
---------------------------------------------------------------------

Microarrays have revolutionized the nuclear receptor field by providing us with snapshots of receptor signaling on genome-wide or near genome-wide scales, and the technique is by far the most heavily used in the field for large-scale studies of gene regulation. Microarrays have been used to dissect nuclear receptor functions both in normal and disease states, in tissues and in cell models. Examples include: numerous studies on nuclear receptor gene regulation for identification of downstream signaling pathways \[[@r37]; [@r55]; [@r75]\]; comparative analyses of gene expression in nuclear receptor null versus wild type mice for several receptors, including VDR, PPAR, and ERR \[[@r9]; [@r39]; [@r82]\]; profiling of drug-induced gene expression through studies of CAR-mediated gene regulation in response to phenobarbital in the liver \[[@r72]\]; identification of PXR-regulated genes encoding phase I, II and III xenobiotic metabolizing enzymes \[[@r59]\]; and comparison in PXR-regulated drug metabolism in intestine and liver to understand and predict drug-drug interactions \[[@r23]\]. Analysis of PPAR activation in a high cholesterol context followed by microarray studies revealed potential target genes of triglyceride-lowering drugs \[[@r16]\]. Microarray technology has also been used to understand the genome-wide effects of environmental estrogens \[[@r48]\]. Nuclear receptor signaling has been analyzed in such diverse disease states as allograft rejection \[[@r3]\] and inflammatory bowel disease \[[@r36]\]. Finally, gene expression patterns have been profiled by microarrays in several models of hormone-dependent cancer for examination of hormonal signal transduction and identification of biomarkers \[[@r11]; [@r20]; [@r24]; [@r33]; [@r38]; [@r55]\], and classification of different cancer types and prediction of patient survival \[[@r17]; [@r21]; [@r24]; [@r78]\].

While there are clearly a wide range of applications for microarrays in studies of nuclear receptor signaling, comparisons between different sets of experiments are not straightforward. Handling the extensive amount of information generated and sorting out the biologically meaningful data from the background noise has been a difficult challenge. MIAME (Minimum Information About a Microarray Experiment \[[@r8]\] focuses on defining the content and structure of data presentation rather than standardization techniques for data analysis. Indeed, comparisons are complicated by differences in sample labeling, hybridization conditions, and imaging quantification techniques. Cut-offs of significant fold regulation used in filtering microarray data, which are often 'noisy' because of stochastic variations in gene expression vary from one study to another. Early experiments used microarrays with far fewer genes than more recent analyses. Moreover, there are no standards for determining statistically significant versus biologically relevant ways to analyze and interpret raw microarray data \[[@r4]\].

Comparative analyses of microarray studies are further complicated by the remarkably limited overlaps in nuclear receptor target genes observed in different experimental models. For example, the vitamin D field has taken full advantage of microarray technology to identify a large number of target genes. Besides its classical physiological function in calcium homeostasis, the hormonal form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25D~3~), regulates cellular proliferation, differentiation, apoptosis, survival, and is a modulator of immune responses. Several studies have shown that 1,25D~3~ arrests cell proliferation at G0/G1 in a variety of models \[[@r2]; [@r32]; [@r43]; [@r42]; [@r68]\]. With such a plethora of biological effects, differences in the types of genes regulated are to be expected between specialized cell types. Nonetheless, apart from the *cyp24* gene, which encodes the enzyme regulating 1,25D~3~ catabolism, the lack of overlap of regulated genes identified in different studies is striking \[[@r79]\]. Some differences are attributable to differential regulation of target genes in different cells. For example, the gene encoding the cyclin-dependent kinase inhibitor p21^WAF1/CIP1^ is strongly induced by 1,25D~3~ in myelomonocytic cells \[[@r45]; [@r50]\], but repressed in 1,25D~3~-sensitive squamous carcinoma cells \[[@r25]; [@r44]\]. However, while the specifics may vary, comparisons of microarrays studies have revealed that 1,25D~3~ signaling regulates the expression of genes controlling cell cycle arrest, DNA repair, markers of cellular differentiation, calcium and redox homeostasis, cell survival and immune responses \[[@r75]\]. The relative lack of overlap of specific gene targets between studies underlines the importance of carefully choosing the cell model that will best represent the physiological responses under investigation.

SAGE and related techniques
---------------------------

SAGE (serial analysis of gene expression), which was developed in the mid-1990's \[[@r80]\], is a technique for gene expression profiling that entails the generation, concatemerization and sequencing of so-called short diagnostic sequence tags. Tags are generated in part by cleavage of cDNA sequences with class II restriction enzymes such as NlaIII, which recognizes frequently occurring CATG recognition sequences and leave 4bp overhangs ([Figure 1](#fig1){ref-type="fig"}). SAGE and its variant longSAGE \[[@r81]\] have been widely used to catalogue gene expression patterns in a number of tissues. Similar to microarray analyses, SAGE has been used to identify hormone-regulated genes in a variety of experimental models \[[@r12]; [@r28]; [@r58]; [@r64]\], as well for comparative studies of gene expression profiles in hormone-dependent and -independent cancers \[[@r1]; [@r15]\].

Although technically quite distinct, the use of SAGE carries some of the same caveats associated with microarray studies. As with microarrays, comparisons between SAGE studies of hormone-regulated gene expression in different tissues or cell types will likely reveal relatively limited overlaps in gene expression profiles. Comparisons between different SAGE studies may be complicated by the number of different statistical methods used to analyze expression patterns in SAGE libraries \[[@r60]\], which, like microarrays, must deal with 'noise' associated with stochastic variations in gene expression. It should also be pointed out that use of SAGE is also technically considerably more demanding than microarrays, and unlike microarray studies which are readily performed in triplicate or more, comparative SAGE analyses are usually performed between single libraries.

Apart from its relative technical complexity SAGE also carries certain inherent drawbacks. Transcripts lacking class II restriction sites used to generate tags will not be detected. In addition, some tags may identify several genomic locations, and the technique can generate artifactual 'orphan' tags via a number of routes \[[@r22]\]. On the other hand, SAGE does have distinct advantages over microarrays \[[@r54]\]. Generation of SAGE libraries requires no *a priori* knowledge mRNA sequences of the organism under study. As indicated above, transcripts identified microarray analyses are limited by the number of sequences on the chip, which is in part limited by knowledge of the transcriptome under study. While this is becoming less limiting for human studies, it is more problematic for analyses of other model organisms with less well characterized transcriptomes. Moreover, multiple transcripts from the same gene can be identified by SAGE, something that is only possible with specialized microarrays bearing sequences of well-characterized genes \[[@r54]\].

Along with 'classical' SAGE, several other tag-based methods have been developed to profile gene expression \[[@r22]\]. These include CAGE ([Figure 1](#fig1){ref-type="fig"}), which generates tags from the 5' ends of transcripts by trapping the mRNA CAPs of full length transcripts. In CAGE, tags are generated by cleavage with Mme1, which is introduced in a ligated linker sequence, thus circumventing the problem of elimination of messages that lack specific restriction enzyme recognition sequences.

Another offshoot of SAGE of interest to nuclear receptor researchers is the SACO (serial analysis of chromatin occupancy) technique \[[@r27]\]. This technique couples chromatin immunoprecipitation using an antibody against a transcription factor (in the case of Impey et al, against CREB) with longSAGE to generate so-called genome signature tags (GSTs). Many of the sequences identified by multiple GSTs in the Impey et al study lay adjacent to known transcription start sites or CpG islands. As SACO can be used to identify potential transcription factor binding sites in addition to target genes, it bears some relation to ChIP-on-chip studies, which is discussed below.

ChIP-on-chip analysis of nuclear receptor binding sites
=======================================================

Overview of the technique
-------------------------

ChIP-on-chip or genome-wide localization analysis was developed a few years ago \[[@r56]\] to identify transcription factor target genes on a chromosome- or genome-wide scale. The technique is a combination of chromatin immunoprecipitation followed by microarray analysis. Briefly, the transcriptional regulator is cross-linked *in vivo* to DNA (chromatin), and the DNA is sheared to \~300-500bp fragments. The transcription factor is immunoprecipitated, and protein complexes are de-crosslinked. The associated DNA is purified, converted into fluorescent-labeled probe and hybridized to a microarray. The advantage of ChIP-on-chip technique is clear; after immunoprecipitation the nuclear receptor can be unambiguously assigned to a specific chromosomal region. There are four types of arrays \[[@r6]\] used for ChIP-on-chip analysis: proximal promoter arrays, where about \~1 kb PCR products encompassing transcription start sites are used as probes; arrays composed of CpG islands amplified by PCR; large promoter arrays, which consist of tiling oligonucleotides of promoter sequences extending up to several kb upstream of the transcription start site; and, finally, the genome tiling array, in which nonrepetive sequence from entire chromosomes is reconstituted from oligonucleotides. When chromosomal sequence is densely covered, very high resolution can be achieved with genome tiling microarrays \[[@r6]\].

ChIP-on-chip analysis of signaling by estrogen receptor α
---------------------------------------------------------

Two recent studies have used ChIP-on-chip approaches to identify ERα binding sites in estrogen-dependent MCF-7 breast cancer cells. Both papers made substantial contributions to understanding estrogen-dependent signaling. However, the two studies are noteworthy for both their similarities and their differences. Both analyzed ERα binding in MCF-7 cells treated for 45 min. with 100 nM estradiol. One study used an Affymetrix tiling array for chromosomes 21/22 \[[@r10]\], and the other used a promoter-specific array composed of 1kb fragments ranging from -800 to +200 bp relative to known transcription start sites \[[@r35]\]. One advantage of chromosomal tiling arrays is their design, and the fact that the results obtained are not dependent on the reliability of previous mapping studies to identify promoter regions. Indeed, Carroll et al \[[@r10]\] cloned by RACE sequences lying several dozen kb upstream of the known 5' end of the gene encoding RIP140 after identifying far upstream EREs on a tiling array. Significantly, in addition to identifying numerous ERα binding sites *in vivo*, both studies provided evidence that the forkhead protein FoxA1 contributes to estrogen-dependent regulation of a number of ERα target genes. Carroll et al \[[@r10]\] reached this conclusion after finding an enrichment of FoxA1 binding sites in the vicinity of EREs characterized on the array.

As ChIP-on-chip approaches use microarrays, they carry the same limitations as other microarray studies. Results will be cell-model and -context specific, with the likelihood of relatively limited overlap between studies performed with different experimental models. Moreover, the number and identity of binding sites will depend on those present on the array. Notably, with the exception of trefoil factor 1 (TFF-1) there was no overlap between the two analyses of ERα binding sites in the two studies cited above, in spite of the use of the same estradiol-treated cell model. Although the microarrays used were different (chromosome 21/22 tiling arrays vs. a short promoter-specific array), there were genes located on chromosomes 21 and 22 identified on the promoter-specific microarray that were not picked up on the tiling array \[[@r10]; [@r35]\]. The study by Carroll et al \[[@r10]\] is remarkable for having identified binding sites located \>100kb from the 5' ends of estrogen target genes. Function of a distal site in the gene encoding RIP140 as an enhancer was verified by chromatin conformation capture assay. Such sites could not have been identified by Laganiere et al \[[@r35]\] because of the use of proximal promoter sequences.

A high percentage of binding sites identified in both studies corresponded to consensus palindromic EREs \[[@r10]; [@r35]\]. Although the palindromic ERE in the TFF-1 gene contains two non consensus substitutions, it represents a high affinity binding site \[[@r7]\]. It is not clear whether the above studies identified only the most high affinity binding sites, or whether the majority of *bona fide* EREs *in vivo* are (near) consensus palindromic elements. Several other studies based largely on reporter gene assays of proximal promoter regions have shown that estrogen responsive promoter elements can be composed of ERE half-sites in association with binding sites for other transcription factors, or that ERα can associate with regulatory regions indirectly by interaction with other DNA-bound proteins \[[@r61]\]. Moreover, it is not clear whether the discrepancies in ERα binding sites on chromosomes 21 and 22 of Carroll et al \[[@r10]\] and Laganiere et al \[[@r35]\] can be attributed to differences in filtering algorithms used to eliminate false positives or other differences in experimental protocols (such as different immunoprecipitating antibodies).

*In silico* hormone response element analyses
=============================================

Overview of the technique
-------------------------

For the purpose of this review, we will refer to *in silico* binding site analysis as the computational techniques used to map consensus or near consensus hormone response elements on a genome wide scale with the aim of identifying potential target genes of the nuclear receptor of interest (as opposed to analysis of a particular promoter for different binding sites to identify regulatory factors). Such approaches have come to the fore with the availability of an increasing number of genome sequences. They have the advantage that they identify response elements at a genome-wide level, whereas microarray or ChIP-on-chip approaches are limited by the number of genes screened and are highly cell context specific. Algorithms are designed with specific "cut-offs" that limit sequences screened to defined distances from known 5' ends of genes. These approaches are powerful and have identified numerous response elements in nuclear receptor target genes, as well as novel target genes (see below). However, the mapping of response elements is limited by the reliability of data used to identify the 5' end(s) of a given gene. Transcription start sites will be thus better defined for genes whose mRNAs have been characterized using techniques to define 5' ends (e.g. 5' RACE, RNase protection). The approach is thus less reliable for genes whose existence is inferred from sequence analysis only.

*In silico* screening for hormone response elements
---------------------------------------------------

The nuclear receptor field has used this type of mapping approach to identify hormone response elements for ERs \[[@r7]; [@r29]; [@r30]; [@r31]; [@r69]\], the AR \[[@r26]; [@r47]\], and the VDR \[[@r74]\]. One issue that must be addressed in setting up such a screen for response elements is how to define a response element consensus. The most rigorous definition of a consensus estrogen response element (ERE) is a palindromic sequence of PuGGTCA half-sites separated by 3 bp \[[@r61]\]. However, different *in silico* studies defined EREs slightly differently. Most used GGTCA as a consensus sequence half-site \[[@r29]; [@r31]; [@r69]\], one defined it as PuGGTC \[[@r40]\], and only one study used PuGGTCA \[[@r7]\]. The study by Bourdeau et al \[[@r7]\] screened the human and mouse genomes from -10 to +5kb of 5' ends for consensus and near consensus EREs based on PuGGTCA motifs and identified conserved and non-conserved elements, often in multiple occurrences, in more than 230 estrogen-regulated human genes previously identified from microarray studies. Significantly, the screen identified distal consensus or near-consensus EREs in genes with previously characterized more degenerate promoter-proximal elements, suggesting that the latter may not be of primary importance in driving the hormonal response. The study showed that a number of distal EREs represented functional binding sites *in vivo* by ChIP assay. A similar screen for VDREs assigned response elements to several hundred 1,25D~3~ target genes identified from microarrays \[[@r74]\], as well as to responsive genes not picked up on arrays. For example, consensus VDREs were found in two genes encoding antimicrobial peptides, *defB4* and *camp*, which led to the discovery that 1,25D~3~ is a direct regulator of antimicrobial innate immunity \[[@r41]; [@r74]\].

Another issue to be addressed in setting up *in silico* screens concerns which non-consensus nucleotide substitutions to include in response element sequences selected for *in silico* screening. Approaches based on nucleotide frequency matrices constructed via compilation of the relatively small number of known natural response elements can identify many variant sequences \[[@r5]; [@r53]\]. For example, a number of putative VDREs containing multiple non-consensus nucleotides have been identified in vitamin D target genes \[[@r71]\]. Many of these sequences were identified in transient expression experiments with overexpressed VDR and reporter plasmids containing limited proximal promoter fragments. While matrix-based algorithms may appropriate for screening defined stretches of promoter regions, screening for numerous highly degenerate elements is impractical as it is difficult to define which elements will be functional. Systematic mutagenesis coupled to electrophoretic mobility shift assays with response element-containing oligonucleotides could be used to identify sequences that bind receptors at levels greater than an arbitrary cut-off (e.g. 25% of a consensus control element). These approaches are reliable for identifying high affinity binding sites *in vitro*. However, Wang et al \[[@r74]\] found that single nucleotide substitutions that disrupted binding *in vitro* were present in VDREs that functioned *in vivo*, as determined by positive results of ChIP assays in many instances, and response element function in reporter gene assays in another. It is likely that receptor affinity for a given response element sequence differs between naked and nucleosomal DNA. Alternatively, affinity of a receptor for a given binding site *in vivo* may be enhanced by association with other transcription factors bound to adjacent sites.

It should also be noted that, apart from the problems associated with identifying the sequences of all potential hormone response elements that are functional *in vivo*, *in silico* screens are limited by the fact that they focus on classical response element-mediated pathways of nuclear receptor regulated gene expression. However, it is now well established that nuclear receptors regulate gene expression by diverse mechanisms \[[@r83]; [@r61]\], including recognition of non-canonical response elements *in vivo*, activation or repression of gene expression through interaction with other classes of transcription factors, and various non-genomic mechanisms.

Another limitation of *in silico* response element screens is the high rates of identification of false positives; i.e., nonregulated genes containing response element sequences. However, these are not easy to identify reliably. Lack of regulation of a gene in a given cell type is not sufficient to eliminate it as a potential target. Although many receptors are widely expressed, many of their target genes are regulated in a cell-specific manner. For example, promoters of the *camp* and *defB4* antimicrobial peptide genes contain proximal, consensus VDREs \[[@r41]\]. Whereas expression of both *defB4* and *camp* was induced by vitamin D in cells of epithelial origin, only *camp* expression was regulated in nonepithelial cells such as monocytes and neutrophils. An analysis of *defB4* regulation in monocytes, would therefore have concluded that the gene represented a false positive. In addition, expression of several nuclear receptor target genes is only modestly affected by ligand treatment. Because expression of many genes is controlled by multiple signal transduction pathways, the effect of ligand may be amplified in the presence of other transducers. These effects could thus be missed if target gene expression is analyzed in the presence of ligand only.

Data generated from an *in silico* screen should be complemented by data from other types of screening techniques, bearing in mind the limitations of each technique. Experimental approaches to verify which sites are functional could include ChIP assays, RT/PCR, microarrays, ChIP-on-chip, with the caveat that these techniques will detect genes regulated in a given tissue/cell type, and should be interpreted in that relatively narrow context. The number of *in silico* hits, including consensus sequences, will generally far out number the number of elements detected in a ChIP-on-chip analysis, and together the two techniques would provide an indication of which regions of chromatin are in a transcriptionally 'open' state.

Support for the potential functionality of a response element identified in an *in silico* screen can be also provided by phylogenetic analysis and demonstration of conservation of element sequence (and location) broadly across species. Certainly, demonstration of broad conservation of a given element is strong evidence for function. However, lack of conservation is not necessarily evidence against function. For example, neither the regulation by 1,25D~3~, nor the consensus VDRE in the human *camp* gene are conserved in rodents, the element having been transposed into the gene on an Alu repeat sometime during primate evolution \[[@r18]; [@r41]\], emphasizing the importance of performing phylogenetic screens as broadly as possible, and not just in species of experimental interest.

Concluding remarks
==================

The rapid evolution of techniques for large-scale genomics studies, such as microarrays and tag-based expression screens, ChIP-on-chip, and *in silico* response element screens, has dramatically advanced our understanding of global gene regulation by nuclear receptors. We have moved from identification of target genes on a gene-by-gene basis to identification of several tens or hundreds of target genes in a single experiment. These approaches have uncovered new physiological actions of nuclear receptors and have revealed the pleiotropic nature of nuclear receptor signaling. However, each technique has its intrinsic strengths and limitations, and different studies are characterized by a remarkably limited overlap in experimental findings. Comparisons of results obtained for signaling by a given receptor using the same technique or across techniques are complicated by the use of different cell/tissue models, platforms, and/or different experimental or bioinformatic protocols. While standardization of protocols (both experimental and bioinformatic) for each technique will minimize to some degree the apparent discrepancies between experiments, the wide variability in experimental results underlines the importance of choosing the appropriate cell/tissue model for analysis of genomic responses underlying the physiological model under scrutiny. Ideally, any rigorous genome-wide analysis of hormone-regulated gene expression in a given experimental system would exploit multiple techniques to generate the most complete and extensively validated data set possible.
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![Generation of tag-based libraries by SAGE and CAGE\
Schematic representations of SAGE (left) and CAGE (right) techniques for generation of tagged expression libraries. In SAGE, mRNA sequences are captured on oligo(dT) magnetic beads (yellow spheres). In CAGE, 5' ends of mRNAs are extracted from total or polyA+ RNA using the CAP-trapper approach. See \[Harbers, 2005\] and \[Porter, 2006\] for details.](nrs04018.f1){#fig1}
